133 related articles for article (PubMed ID: 17351930)
1. Oral antiplatelet therapy for percutaneous coronary revascularization.
Hamdalla H; Steinhubl SR
Catheter Cardiovasc Interv; 2007 Apr; 69(5):637-42. PubMed ID: 17351930
[TBL] [Abstract][Full Text] [Related]
2. Current antiplatelet therapies: benefits and limitations.
Angiolillo DJ; Guzman LA; Bass TA
Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
[TBL] [Abstract][Full Text] [Related]
3. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
5. [Antiplatelet therapy during coronary endoprosthesis placement].
Barragan P; Pietri P; Villain P; Silvestri M; Roquebert PO
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1515-20. PubMed ID: 9092412
[TBL] [Abstract][Full Text] [Related]
6. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
7. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
8. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
9. Platelet inhibition in percutaneous coronary interventions.
Wyss CA; Roffi M
Herz; 2005 May; 30(3):189-96. PubMed ID: 15902369
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
[TBL] [Abstract][Full Text] [Related]
11. Optimal antithrombotic treatment for percutaneous coronary intervention.
Kadakia RA; Ferguson JJ
Minerva Cardioangiol; 2005 Feb; 53(1):15-42. PubMed ID: 15788977
[TBL] [Abstract][Full Text] [Related]
12. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
[TBL] [Abstract][Full Text] [Related]
13. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Thomas D; Giugliano RP
Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of antiplatelet therapy.
Wiviott SD; Tantry US; Gurbel PA; ;
Rev Cardiovasc Med; 2006; 7(3):130-46; quiz 148-9. PubMed ID: 17088858
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet agents in cardiology: the choice of therapy.
Steinhubl SR
Ann Thorac Surg; 2000 Aug; 70(2 Suppl):S3-8. PubMed ID: 10966004
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
Cohen M
Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
[TBL] [Abstract][Full Text] [Related]
18. [Resistance to antiplatelet substances--a real clinical problem].
Geisler T; Gawaz M
Herz; 2008 Jun; 33(4):260-8. PubMed ID: 18581075
[TBL] [Abstract][Full Text] [Related]
19. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
[TBL] [Abstract][Full Text] [Related]
20. Platelet activation and progression to complications.
Kereiakes DJ; Michelson AD
Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
